annual EBITDA:
-$45.85M-$16.65M(-57.00%)Summary
- As of today (May 28, 2025), RGLS annual EBITDA is -$45.85 million, with the most recent change of -$16.65 million (-57.00%) on December 31, 2024.
- During the last 3 years, RGLS annual EBITDA has fallen by -$19.36 million (-73.07%).
- RGLS annual EBITDA is now -652.04% below its all-time high of -$6.10 million, reached on December 31, 2011.
Performance
RGLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$9.53M+$3.16M(+24.89%)Summary
- As of today (May 28, 2025), RGLS quarterly EBITDA is -$9.53 million, with the most recent change of +$3.16 million (+24.89%) on March 31, 2025.
- Over the past year, RGLS quarterly EBITDA has dropped by -$1.23 million (-14.75%).
- RGLS quarterly EBITDA is now -1229.43% below its all-time high of -$717.00 thousand, reached on September 30, 2011.
Performance
RGLS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$47.08M-$1.23M(-2.67%)Summary
- As of today (May 28, 2025), RGLS TTM EBITDA is -$47.08 million, with the most recent change of -$1.23 million (-2.67%) on March 31, 2025.
- Over the past year, RGLS TTM EBITDA has dropped by -$16.47 million (-53.82%).
- RGLS TTM EBITDA is now -6465.97% below its all-time high of -$717.00 thousand, reached on September 30, 2011.
Performance
RGLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RGLS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -57.0% | -14.8% | -53.8% |
| 3 y3 years | -73.1% | -45.8% | -70.8% |
| 5 y5 years | -195.3% | -78.8% | -152.1% |
RGLS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -73.1% | at low | -45.8% | +31.8% | -71.1% | at low |
| 5 y | 5-year | -240.8% | at low | -1065.3% | +31.8% | -262.3% | at low |
| alltime | all time | -652.0% | +41.5% | -1229.4% | +56.2% | -6466.0% | +39.9% |
RGLS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$9.53M(-24.9%) | -$47.08M(+2.7%) |
| Dec 2024 | -$45.85M(+57.0%) | -$12.69M(-9.1%) | -$45.85M(+11.7%) |
| Sep 2024 | - | -$13.97M(+28.3%) | -$41.03M(+18.3%) |
| Jun 2024 | - | -$10.89M(+31.1%) | -$34.70M(+13.4%) |
| Mar 2024 | - | -$8.31M(+5.5%) | -$30.61M(+4.8%) |
| Dec 2023 | -$29.20M(+6.2%) | -$7.87M(+3.1%) | -$29.20M(+4.7%) |
| Sep 2023 | - | -$7.63M(+12.3%) | -$27.90M(+1.0%) |
| Jun 2023 | - | -$6.80M(-1.6%) | -$27.61M(-1.0%) |
| Mar 2023 | - | -$6.91M(+5.2%) | -$27.88M(+1.3%) |
| Dec 2022 | -$27.51M(+3.8%) | -$6.57M(-10.6%) | -$27.51M(-1.1%) |
| Sep 2022 | - | -$7.34M(+3.9%) | -$27.82M(-3.6%) |
| Jun 2022 | - | -$7.07M(+8.1%) | -$28.86M(+4.7%) |
| Mar 2022 | - | -$6.54M(-5.0%) | -$27.57M(+4.1%) |
| Dec 2021 | -$26.49M(+96.9%) | -$6.88M(-17.9%) | -$26.49M(+29.7%) |
| Sep 2021 | - | -$8.38M(+45.2%) | -$20.43M(+57.2%) |
| Jun 2021 | - | -$5.77M(+5.7%) | -$12.99M(-4.4%) |
| Mar 2021 | - | -$5.46M(+567.7%) | -$13.59M(+1.0%) |
| Dec 2020 | -$13.46M(-13.4%) | -$818.00K(-13.3%) | -$13.46M(-20.4%) |
| Sep 2020 | - | -$943.00K(-85.2%) | -$16.90M(-18.5%) |
| Jun 2020 | - | -$6.36M(+19.4%) | -$20.73M(+11.0%) |
| Mar 2020 | - | -$5.33M(+25.1%) | -$18.68M(+20.3%) |
| Dec 2019 | -$15.53M(-64.7%) | -$4.26M(-10.8%) | -$15.53M(-16.9%) |
| Sep 2019 | - | -$4.78M(+11.0%) | -$18.68M(-18.8%) |
| Jun 2019 | - | -$4.31M(+97.5%) | -$23.00M(-26.7%) |
| Mar 2019 | - | -$2.18M(-70.6%) | -$31.37M(-28.8%) |
| Dec 2018 | -$44.04M | -$7.42M(-18.5%) | -$44.04M(-11.1%) |
| Sep 2018 | - | -$9.10M(-28.1%) | -$49.56M(-10.1%) |
| Jun 2018 | - | -$12.67M(-14.7%) | -$55.13M(-12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$14.86M(+14.9%) | -$62.93M(-5.9%) |
| Dec 2017 | -$66.86M(-14.7%) | -$12.93M(-11.9%) | -$66.86M(-8.1%) |
| Sep 2017 | - | -$14.67M(-28.4%) | -$72.75M(-4.7%) |
| Jun 2017 | - | -$20.48M(+9.0%) | -$76.37M(-0.0%) |
| Mar 2017 | - | -$18.78M(-0.2%) | -$76.39M(-2.5%) |
| Dec 2016 | -$78.38M(+44.8%) | -$18.82M(+2.9%) | -$78.38M(+18.2%) |
| Sep 2016 | - | -$18.29M(-10.8%) | -$66.34M(+9.3%) |
| Jun 2016 | - | -$20.50M(-1.3%) | -$60.68M(-0.2%) |
| Mar 2016 | - | -$20.77M(+206.4%) | -$60.80M(+12.3%) |
| Dec 2015 | -$54.12M(-1.9%) | -$6.78M(-46.3%) | -$54.12M(-21.7%) |
| Sep 2015 | - | -$12.63M(-38.8%) | -$69.11M(+4.9%) |
| Jun 2015 | - | -$20.63M(+46.4%) | -$65.87M(+15.8%) |
| Mar 2015 | - | -$14.09M(-35.3%) | -$56.86M(+3.1%) |
| Dec 2014 | -$55.15M(+218.9%) | -$21.77M(+131.8%) | -$55.15M(+57.8%) |
| Sep 2014 | - | -$9.39M(-19.2%) | -$34.95M(+27.8%) |
| Jun 2014 | - | -$11.62M(-6.1%) | -$27.36M(+20.4%) |
| Mar 2014 | - | -$12.38M(+687.7%) | -$22.72M(+31.4%) |
| Dec 2013 | -$17.30M(+7.1%) | -$1.57M(-12.5%) | -$17.30M(-22.6%) |
| Sep 2013 | - | -$1.79M(-74.3%) | -$22.35M(-13.6%) |
| Jun 2013 | - | -$6.98M(+0.4%) | -$25.88M(+22.2%) |
| Mar 2013 | - | -$6.95M(+4.8%) | -$21.18M(+31.1%) |
| Dec 2012 | -$16.15M(+164.9%) | -$6.63M(+24.6%) | -$16.15M(+45.3%) |
| Sep 2012 | - | -$5.32M(+133.9%) | -$11.11M(+70.7%) |
| Jun 2012 | - | -$2.27M(+18.0%) | -$6.51M(+53.7%) |
| Mar 2012 | - | -$1.93M(+21.3%) | -$4.24M(+83.6%) |
| Dec 2011 | -$6.10M(-58.6%) | -$1.59M(+121.8%) | -$2.31M(+221.8%) |
| Sep 2011 | - | -$717.00K | -$717.00K |
| Dec 2010 | -$14.73M | - | - |
FAQ
- What is Regulus Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Regulus Therapeutics?
- What is Regulus Therapeutics annual EBITDA year-on-year change?
- What is Regulus Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Regulus Therapeutics?
- What is Regulus Therapeutics quarterly EBITDA year-on-year change?
- What is Regulus Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Regulus Therapeutics?
- What is Regulus Therapeutics TTM EBITDA year-on-year change?
What is Regulus Therapeutics annual EBITDA?
The current annual EBITDA of RGLS is -$45.85M
What is the all time high annual EBITDA for Regulus Therapeutics?
Regulus Therapeutics all-time high annual EBITDA is -$6.10M
What is Regulus Therapeutics annual EBITDA year-on-year change?
Over the past year, RGLS annual EBITDA has changed by -$16.65M (-57.00%)
What is Regulus Therapeutics quarterly EBITDA?
The current quarterly EBITDA of RGLS is -$9.53M
What is the all time high quarterly EBITDA for Regulus Therapeutics?
Regulus Therapeutics all-time high quarterly EBITDA is -$717.00K
What is Regulus Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RGLS quarterly EBITDA has changed by -$1.23M (-14.75%)
What is Regulus Therapeutics TTM EBITDA?
The current TTM EBITDA of RGLS is -$47.08M
What is the all time high TTM EBITDA for Regulus Therapeutics?
Regulus Therapeutics all-time high TTM EBITDA is -$717.00K
What is Regulus Therapeutics TTM EBITDA year-on-year change?
Over the past year, RGLS TTM EBITDA has changed by -$16.47M (-53.82%)